Alumis Inc. (NASDAQ:ALMS) CEO Martin Babler Acquires 15,650 Shares

Alumis Inc. (NASDAQ:ALMS) CEO Martin Babler acquired 15,650 shares of the stock in a transaction dated Tuesday, April 1st. The shares were bought at an average price of $6.44 per share, for a total transaction of $100,786.00. Following the transaction, the chief executive officer now owns 106,454 shares in the company, valued at approximately $685,563.76. This represents a 17.23 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Alumis Trading Up 17.7 %

Shares of ALMS stock opened at $10.05 on Friday. Alumis Inc. has a fifty-two week low of $3.18 and a fifty-two week high of $13.53. The stock has a 50 day moving average price of $5.52 and a two-hundred day moving average price of $8.24.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on ALMS shares. Cantor Fitzgerald restated an “overweight” rating on shares of Alumis in a research report on Thursday, March 20th. HC Wainwright reissued a “buy” rating and set a $15.00 price objective on shares of Alumis in a report on Wednesday, March 26th. Finally, Oppenheimer initiated coverage on Alumis in a research note on Thursday, January 30th. They issued an “outperform” rating and a $32.00 target price for the company. Seven equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus price target of $26.00.

Institutional Investors Weigh In On Alumis

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ALMS. Foresite Capital Management VI LLC purchased a new position in shares of Alumis in the fourth quarter valued at about $33,033,000. Samsara BioCapital LLC bought a new stake in shares of Alumis in the third quarter worth about $34,886,000. Geode Capital Management LLC purchased a new position in Alumis during the 3rd quarter valued at about $3,266,000. Norges Bank bought a new position in Alumis during the 4th quarter valued at approximately $1,606,000. Finally, Foresite Capital Management V LLC lifted its holdings in Alumis by 3.5% in the 4th quarter. Foresite Capital Management V LLC now owns 5,779,348 shares of the company’s stock worth $45,426,000 after buying an additional 194,459 shares during the period.

Alumis Company Profile

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.